Fig. 2: Broadly neutralizing potency of mAbs against SARS-CoV-2 variants.
From: Structural basis of spike RBM-specific human antibodies counteracting broad SARS-CoV-2 variants
a Dose-response analysis of the neutralization by each mAb NCV1SG17, NCV1SG23, NCV2SG48, NCV2SG53, REGN10933, and REGN10987 on indicated variants of SARS-CoV-2 pseudovirus. The horizontal dotted line on each graph indicates 50% neutralization. Data are mean ± SEM of technical replicates from 2 to 3 independent experiments. b The IC50 neutralization values of each and the mixture of mAbs against indicated pseudoviruses of the SARS-CoV-2 variant. NCV2SG48-GL, germline revertant of NCV2SG48.
